JPH075459B2 - Anti-alcoholic liver injury composition - Google Patents
Anti-alcoholic liver injury compositionInfo
- Publication number
- JPH075459B2 JPH075459B2 JP4281140A JP28114092A JPH075459B2 JP H075459 B2 JPH075459 B2 JP H075459B2 JP 4281140 A JP4281140 A JP 4281140A JP 28114092 A JP28114092 A JP 28114092A JP H075459 B2 JPH075459 B2 JP H075459B2
- Authority
- JP
- Japan
- Prior art keywords
- alanine
- present
- liver injury
- alcoholic liver
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、アルコール性肝障害等
の抗肝障害作用を有する食品又は医薬組成物に関する。TECHNICAL FIELD The present invention relates to a food or pharmaceutical composition having an anti-hepatic disorder action such as alcoholic liver disorder.
【０００２】[0002]
【従来の技術】アルコール性肝障害は、二日酔い症状や
軽度の意識障害から、昏睡、昏迷状態、或いは肝細胞の
壊死に起因する肝機能不全による致死までの種々の障害
所見を呈する。このような肝障害を軽減し、若しくは、
治癒する目的で、プロトポルフィリン系製剤、グルクロ
ン酸製剤等並びに、アルギニン塩酸塩等のアミノ酸製剤
などが従来用いられてきた。2. Description of the Related Art Alcoholic liver damage presents various disorders such as hangover symptoms and mild consciousness disorder, coma, stupor, and death due to liver dysfunction caused by necrosis of hepatocytes. Reduce such liver damage, or
For the purpose of healing, protoporphyrin-based preparations, glucuronic acid preparations and the like, and amino acid preparations such as arginine hydrochloride and the like have been conventionally used.
【０００３】アミノ酸としては、この他、バリン、ロイ
シン、イソロイシン等の分枝鎖アミノ酸、特にバリンの
投与が肝性昏睡患者の容態の急激な回復に有効であると
の知見（特公昭５７−２９４４６）や、オルニチンが肝
性昏睡において肝臓におけるアンモニアの解毒***機能
を改善する等の知見が存在するが、肝障害自体を改善す
るとは知られていない。また、オルニチンについては、
アデノシン三燐酸との塩が上記アンモニアの解毒***に
すぐれた効果を発揮することも報告されている（特公昭
４１−９３１６）。In addition to these amino acids, it has been found that the administration of branched-chain amino acids such as valine, leucine and isoleucine, especially valine, is effective for the rapid recovery of the condition of patients with hepatic coma (Japanese Patent Publication No. 57-29446). ), Ornithine improves the detoxification and excretion function of ammonia in the liver in hepatic coma, but it is not known to improve liver damage itself. For ornithine,
It has also been reported that a salt with adenosine triphosphate has an excellent effect on detoxification and excretion of ammonia (Japanese Patent Publication No. 41-9316).
【０００４】[0004]
【発明が解決しようとする課題】本発明は、医薬の投与
による治癒的回復手段に限定されがちであったアルコー
ル性肝障害の軽減乃至は回復を、治癒効果のみならず、
予防にもすぐれた効果を発揮する物質を食品等の自然な
形態で摂取せしむることにより、治癒を行うことを目的
とする。DISCLOSURE OF THE INVENTION The present invention aims to reduce or recover alcoholic liver damage, which was apt to be limited to a curative recovery means by administration of a drug, in addition to a curative effect.
The purpose is to heal by ingesting substances that exhibit excellent effects in prevention in natural forms such as foods.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、アルコー
ルの大量投与による肝ミトコンドリア障害による代謝変
動を考究する中で、絶食後のマウスを用いた大量のアル
コール負荷実験にて、救命効果を有する物質を見い出し
た。即ち、アラニン等数種のアミノ酸に救命効果及び肝
障害改善効果が認められた。[Means for Solving the Problems] While investigating the metabolic changes due to hepatic mitochondrial damage caused by the administration of a large amount of alcohol, the present inventors have shown a life-saving effect in a large amount of alcohol loading experiment using fasted mice. Found the substance that has. That is, several kinds of amino acids such as alanine were found to have a life-saving effect and a liver damage-improving effect.
【０００６】本発明は、アラニン又はその塩を有効成分
として含有する（但し、オルニチン及び／又はその塩を
も含有する場合を除く）抗アルコール性肝障害組成物で
ある。The present invention contains alanine or a salt thereof as an active ingredient ( provided that ornithine and / or a salt thereof is
It is an anti-alcoholic liver injury composition.
【０００７】〔実験例〕 マウスの大量アルコール負荷
実験 実験法：ＪＣＩ：ＩＣＲ系の生後約６週間のマウスを用
い、約２０時間絶食（水分可）後に表１に示す検定物質
（０．９％ＮａＣｌ液中の０．１又は０．０２５Ｍ、ｐ
Ｈ７．４）を腹腔内に注射し、対照には、同量の０．９
％ＮａＣｌ液を腹腔内に注射した。その約４０分後に、
０．９％ＮａＣｌ液中の１９％Ｗ／Ｖのエタノール１７
０mmol／kg体重を腹腔内に注射し、その後５日間の生存
率を調べた。[Experimental Example] Large-scale alcohol tolerance test in mice Experimental method: JCI: ICR strain mice of about 6 weeks old were used, and the test substances (0.9%) shown in Table 1 were obtained after fasting for about 20 hours (allowing water). 0.1 or 0.025M in NaCl solution, p
H7.4) was injected intraperitoneally and the control contained the same amount of 0.9.
% NaCl solution was injected intraperitoneally. About 40 minutes later,
19% W / V ethanol 17 in 0.9% NaCl solution
An intraperitoneal injection of 0 mmol / kg body weight was performed, and the survival rate for 5 days was examined.
【０００８】結果：表１に示す如く、４０匹の対照群で
は、生存率は３５％であった。各種アミノ酸、グルコー
スや各種有機酸の救命効果を調べた。その結果、アラニ
ン、スレオニン、ロイシンやイソロイシンなどのアミノ
酸にやや強い救命効果が見られた。アラニン単独の場
合、生存率は６７％であった。Results: As shown in Table 1, in the control group of 40 animals, the survival rate was 35%. The life-saving effects of various amino acids, glucose and various organic acids were investigated. As a result, amino acids such as alanine, threonine, leucine and isoleucine were found to have a rather strong life-saving effect. With alanine alone, the survival rate was 67%.
【０００９】[0009]
【表１】 [Table 1]
【００１０】アラニン投与群では体重の増加も対照群に
比べて大であった。対照群の肝組織像は、Ｈ−Ｅ染色
で、中心静脈周囲に、変生、腫大した肝細胞が著明に見
られたが、アラニン投与群は肝組織障害が軽減されてい
た。アラニンとしては、Ｌ−アラニン又はＤＬ−アラニ
ン又はそれらの塩酸塩等何れでも用いうる。The increase in body weight in the alanine administration group was also larger than that in the control group. In the liver tissue image of the control group, metamorphosed and swollen hepatocytes were clearly seen around the central vein by HE staining, but the liver tissue damage was reduced in the alanine administration group. As alanine, any of L-alanine, DL-alanine, or their hydrochlorides can be used.
【００１１】本発明の組成物は、医薬又は食品の形態で
提供できる。医薬は、経口的に又は非経口的に適用され
得る。本発明の医薬が提供される形態としては、経口投
与用には、例えば、散剤、顆粒、錠剤、糖衣錠、カプセ
ル、液剤等、非経口投与用には例えば、懸濁液、液剤、
乳剤、アンプル及び注射液等が挙げられ、或いは、これ
らを組合せた形態でも提供できる。組合せ得る希釈剤と
しては、固体、半固体及び液体のいずれでもよく、例え
ば、水、ゼラチン、糖類、澱粉類、脂肪酸、その塩、ア
ルコール、油脂、タルク、生理食塩水等又はこれらの２
種以上の組合せが挙げられる。本発明医薬におけるアラ
ニン又はその塩の重量が占める割合は、一般に０．０１
〜１００重量％である。The composition of the present invention can be provided in the form of a medicine or food. The medicament may be applied orally or parenterally. As a form in which the medicament of the present invention is provided, for oral administration, for example, powders, granules, tablets, dragees, capsules, solutions and the like, for parenteral administration, for example, suspensions, solutions,
Examples thereof include emulsions, ampoules, and injection solutions, or a combination of these can be provided. The diluent that can be combined may be solid, semi-solid or liquid, and examples thereof include water, gelatin, saccharides, starches, fatty acids, salts thereof, alcohols, oils and fats, talc, physiological saline and the like or two of these.
Combinations of more than one species are included. The proportion of the weight of alanine or a salt thereof in the medicine of the present invention is generally 0.01.
~ 100% by weight.
【００１２】一方、本発明組成物は、食品として極めて
有効に提供し得る。好ましい食品の形態としては、アル
コール類と同時に、或いは相前後して摂取される食品で
あり、具体的には、くんせい、サキイカ、塩カラ、カラ
スミ、イクラ、明太子、タラ子、キャビア、フォアグ
ラ、腐乳、豆腐、チーズ、ポテトチップ、米菓、豆菓子
その他のいわゆる酒の肴、つまみ類として常用される高
蛋白質系食品、高油脂系食品、高澱粉質系食品の類、或
いは、焼肉のタレ、刺身醤油、湯豆腐・冷奴のタレ、ド
レッシング・マヨネーズ等のソース類、ラー油、食酢、
食卓塩等の調味料、更に、日本酒、ビール、焼酎、ワイ
ン、ウィスキー、ブランディー、老酒、ジン、ラム、カ
ンパリ、ヴェルモット、各種のカクテル類等のアルコー
ル飲料・スポーツドリンク、トマトジュースその他のジ
ュース、コーラ等のソフトドリンク類などが挙げられ
る。On the other hand, the composition of the present invention can be very effectively provided as a food. As a preferable form of food, it is a food that is ingested at the same time as alcohols, or before and after, specifically, Kunsei, squid, salted kara, karasumi, salmon roe, mentaiko, cod roe, caviar, foie gras, Soiled milk, tofu, cheese, potato chips, rice crackers, bean confectionery and other so-called liquor dishes, high-protein foods, high-fat foods, high-starch foods commonly used as snacks, or grilled meat sauce , Sashimi soy sauce, hot tofu / cold tofu sauce, sauces such as dressing / mayonnaise, chili oil, vinegar,
Seasoning such as table salt, and also alcoholic drinks / sports drinks such as sake, beer, shochu, wine, whiskey, brandy, old sake, gin, lamb, campari, vermouth, various cocktails, tomato juice and other juices, Examples include soft drinks such as cola.
【００１３】本発明の食品におけるアラニン及び／又は
それらの塩の重量の占める比率は、一般に０．０１〜１
０％である。官能面で、本発明のアラニンの高濃度での
使用が好ましくない場合、例えば、比較的高融点の油
脂、蛋白、澱粉等でカプセル化して用いるか、或いは、
マスキング剤を併用する等の方法の採用が好ましい。ま
た、本発明の組成物を医薬として用いる場合は、経口投
与用には散剤、顆粒、錠剤、糖衣錠、カプセル、液剤等
の形で、また非経口投与用には懸濁液、液剤、アンプル
及び注射液等の形態で用いられる。尚、本発明組成物
は、アラニン及び／又はその塩を必須の有効成分として
含有するが、その他のアミノ酸類の共存は、本発明の目
的を逸脱しない限り、可能なことはいうまでもない。The weight ratio of alanine and / or salts thereof in the food of the present invention is generally 0.01 to 1.
It is 0%. On the sensory side, when it is not preferable to use the alanine of the present invention at a high concentration, for example, oil or fat having a relatively high melting point, protein, or the like is used after being encapsulated, or
It is preferable to employ a method such as using a masking agent together. When the composition of the present invention is used as a medicine, it is in the form of powder, granules, tablets, dragees, capsules, solutions for oral administration, and suspensions, solutions, ampoules and the like for parenteral administration. It is used in the form of injection solution and the like. Although the composition of the present invention contains alanine and / or a salt thereof as an essential active ingredient, it goes without saying that coexistence of other amino acids is possible without departing from the object of the present invention.
【００１４】本発明のアラニンの投与による大量アルコ
ール負荷実験にみられる如く、肝障害所見の軽減が得ら
れ、強い救命効果が認められた。本発明のアラニンの投
与量は肝障害の程度及び自他覚症状にもよるが大人１人
当り１〜２０ｇ／日であり、１〜６ｇの範囲内の量が好
ましい。なお、アラニンは天然のたんぱく質中に存在し
ているアミノ酸の一種であり、大量に投与しても急性毒
性は認められない。As seen in the large-amount alcohol tolerance experiment by the administration of alanine of the present invention, the findings of liver injury were reduced, and a strong life-saving effect was recognized. The dose of alanine of the present invention depends on the degree of liver damage and subjective symptoms, but is 1 to 20 g / day per adult, and the amount is preferably in the range of 1 to 6 g. Alanine is a kind of amino acid existing in natural proteins, and no acute toxicity is observed even if it is administered in a large amount.
【００１５】次に本発明の実施例を示す。 実施例１ ドリンク剤に、アラニンを、アラニンが６ｇ／dlとなる
ように添加した。得られたドリンク剤を前記実験例と同
じアラニン量となるように、腹腔内に注射した以外は、
実験例と同様に救命効果を調べたところ、該実験例と同
様な効果が得られた。Next, examples of the present invention will be described. Example 1 Alanine was added to a drink at an alanine content of 6 g / dl. So that the obtained drink agent has the same amount of alanine as in the experimental example, except that it was injected intraperitoneally,
When the life-saving effect was examined in the same manner as in the experimental example, the same effect as in the experimental example was obtained.
Claims (1)
して含有する（但し、オルニチン及び／又はその塩をも
含有する場合を除く）抗アルコール性肝障害組成物。1. Alanine and / or a salt thereof is contained as an active ingredient (provided that ornithine and / or a salt thereof is also included.
(Except when contained) Antialcoholic liver injury composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4281140A JPH075459B2 (en) | 1992-09-28 | 1992-09-28 | Anti-alcoholic liver injury composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4281140A JPH075459B2 (en) | 1992-09-28 | 1992-09-28 | Anti-alcoholic liver injury composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59172793A Division JPS6150917A (en) | 1984-08-20 | 1984-08-20 | Remedying composition for alcoholic hepatopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05213746A JPH05213746A (en) | 1993-08-24 |
| JPH075459B2 true JPH075459B2 (en) | 1995-01-25 |
Family
ID=17634926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4281140A Expired - Lifetime JPH075459B2 (en) | 1992-09-28 | 1992-09-28 | Anti-alcoholic liver injury composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH075459B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1072264A4 (en) | 1998-04-16 | 2004-07-28 | Ajinomoto Kk | Remedies for primary biliary cirrhosis |
| AU2003261825A1 (en) * | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150917A (en) * | 1984-08-20 | 1986-03-13 | Ajinomoto Co Inc | Remedying composition for alcoholic hepatopathy |
-
1992
- 1992-09-28 JP JP4281140A patent/JPH075459B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05213746A (en) | 1993-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7455872B2 (en) | Compositions and methods for producing a salty taste in foods or beverages | |
| US6855727B2 (en) | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect | |
| WO1999066917A2 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| JPH0920661A (en) | Learning ability-improving composition | |
| US4596825A (en) | Method of treating liver disturbances resulting from alcohol consumption and a composition therefor | |
| JPH0952828A (en) | Amino acid composition and its use | |
| JP2002065212A (en) | Food composition for strengthening muscle, and muscle- strengthening agent | |
| KR101219146B1 (en) | Protein hydrolysate with antidiabetic effect | |
| RU2372900C2 (en) | Inhibitor of contraction and development of liver cancer to be applied in hepatitis c positive patients suffering from cirrhosis | |
| Felber | A Survey of the Effect of Other Ammo-acids on the Absorption of L-arginine and L-lysine by the Rat Intestine | |
| KR20050072096A (en) | Amino acid compositions for improving central functions | |
| JPH0420409B2 (en) | ||
| JP3908513B2 (en) | Liver function improving agent | |
| EP3174548B1 (en) | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose | |
| JPH075459B2 (en) | Anti-alcoholic liver injury composition | |
| JP4864064B2 (en) | Peptide having anti-diabetic action and use thereof | |
| JP4395658B2 (en) | Composition for inhibiting cholesterol re-elevation and method of use thereof | |
| US20080058264A1 (en) | Amino-acid containing composition for inhibiting accumulation of fat | |
| AU692903B2 (en) | Hemopoietic function-stimulating agent | |
| JP2007031403A (en) | Lactic acid production inhibitor | |
| JP2002173442A (en) | Antifatigue composition | |
| JP2022001029A (en) | Dipeptidyl peptidase iv inhibitor and food composition containing the same | |
| JP3712539B2 (en) | Liver disease treatment | |
| JPH0881372A (en) | Preventive/therapeutic agent for medical symptom due to decrease in erytherocyte number | |
| TWI714413B (en) | Blood pressure increase inhibitor using pig cartilage extract containing chondroitin sulfate as an active ingredient and food composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |